Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/24351
Title: Transcriptional variability accelerates pre-leukemia by cell diversification and 2 perturbation of protein synthesis
Authors: Gupta, S
Dovey, OM
Domingues, AF
Cyran, OW
Cash, CM
Giotopoulos, G
Rak, J
Cooper, J
Gozdecka, M
Asby, RJ
Al-Jabery, N
Hernandez, V
Prabakaran, S
Huntly, BJ
Vassiliou, GS
Pina, C
Issue Date: 19-Oct-2021
Publisher: Cold Spring Harbor Laboratory
Citation: Gupta, S., Dovey, O.M., Domingues, A.F., Cyran, O.W., Cash, C.M., Giotopoulos, G., Rak, J., Cooper, J., Gozdecka, M., Asby, R.J., Al-Jabery, N., Hernandez, V., Prabakaran, S., Huntly, B.J., Vassiliou, G.S. and Pina C. (2021) biorXiv preprint, 2021.10.18.464824, pp. 1-15. doi: 10.1101/2021.10.18.464824.
Abstract: Copyright 2021 The Authors. Transcriptional variability facilitates stochastic cell diversification and can in turn underpin adaptation to stress or injury. We hypothesize that it may analogously facilitate progression of pre-malignancy to cancer. To investigate this, we initiated pre-leukemia in mouse cells with enhanced transcriptional variability due to conditional disruption of the histone lysine acetyltransferase gene Kat2a. By combining single-cell RNA-sequencing of pre-leukemia with functional analysis of transformation, we show that Kat2a loss results in global variegation of cell identity and accumulation of pre-leukemic cells. Leukemia progression is subsequently facilitated by destabilization of ribosome biogenesis and protein synthesis, which confer a transient transformation advantage. The contribution of transcriptional variability to early cancer evolution reflects a generic role in promoting cell fate transitions, which, in the case of well-adapted malignancies, contrastingly differentiates and depletes cancer stem cells. In other words, transcriptional variability confers forward momentum to cell fate systems, with differential multi-stage impact throughout cancer evolution.
Description: Competing Interest Statement: VH-H is co-Founder and CSO of Axovia Therapeutics. SP is the CEO of NonExomics, Inc. Axovia and NonExomics did not provide funding to this study, and did not influence study design, execution, data analysis or interpretation.
bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.
URI: https://bura.brunel.ac.uk/handle/2438/24351
DOI: https://doi.org/10.1101/2021.10.18.464824
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
Preprint.pdf3.07 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons